Important Notice [Statement by the Board of Directors, Supervisory Board, and Senior Management](index=2&type=section&id=Statement%20by%20the%20Board%20of%20Directors%2C%20Supervisory%20Board%2C%20and%20Senior%20Management) The company's Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, assuming legal responsibility; this report is unaudited - The company's Board of Directors, Supervisory Board, and directors, supervisors, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, free from false statements, misleading representations, or major omissions, and assume individual and joint legal liabilities[7](index=7&type=chunk) - This semi-annual report has not been audited[7](index=7&type=chunk) [Risk Statement and Disclaimer](index=2&type=section&id=Risk%20Statement%20and%20Disclaimer) Forward-looking statements in this report do not constitute a substantive commitment; investors are advised to review Section III for detailed risks and countermeasures - Forward-looking descriptions in this report, such as future plans and development strategies, do not constitute a substantive commitment to investors; please be aware of investment risks[5](index=5&type=chunk) - The company has detailed the various risks and countermeasures it may face in its production and operations in this report; please refer to 'Risks We May Face' in Section III 'Management Discussion and Analysis'[6](index=6&type=chunk) Section I Definitions [Definitions of Common Terms](index=4&type=section&id=Definitions%20of%20Common%20Terms) This section defines common terms, including company names, related parties, industry jargon (e.g., POCT, FDA, CE), and the reporting period, ensuring clear understanding of professional terminology - The Company, Company, Getian Bio refers to Getian Bio-Tech Co., Ltd[10](index=10&type=chunk) - Reporting Period, within the Reporting Period refers to January 1, 2021 - June 30, 2021[10](index=10&type=chunk) - POCT refers to the acronym for 'Point Of Care Testing', translated as 'Point-of-Care Testing'[10](index=10&type=chunk) - FDA is the English abbreviation for the U.S. Food and Drug Administration, an agency of the U.S. Department of Health and Human Services, responsible for regulating drugs, food, biological products, cosmetics, veterinary drugs, medical devices, and diagnostic products nationwide[10](index=10&type=chunk)[11](index=11&type=chunk) Section II Company Profile and Key Financial Indicators [Company Basic Information](index=6&type=section&id=Company%20Basic%20Information) This section provides the company's Chinese and English names, legal representative, contact details, registered and office addresses, website, email, and information disclosure channels - The company's Chinese name is Getian Bio-Tech Co., Ltd., and its Chinese abbreviation is Getian Bio[14](index=14&type=chunk) - The company's legal representative is Su Enben, and the Board Secretary is Liu Cong[14](index=14&type=chunk)[15](index=15&type=chunk) - The company's registered and office address is No. 9 Bofu Road, Yanjiang Industrial Development Zone, Luhe District, Nanjing City[16](index=16&type=chunk) - The company's designated information disclosure newspapers are 'Shanghai Securities News' and 'Securities Times', and the website for the semi-annual report is www.sse.com.cn[17](index=17&type=chunk) [Company Stock Overview](index=6&type=section&id=Company%20Stock%20Overview) The company's A-shares are listed on the Shanghai Stock Exchange under the stock name Getian Bio and stock code 603387 - The company's stock type is A-shares, listed on the Shanghai Stock Exchange, with stock abbreviation Getian Bio and stock code 603387[18](index=18&type=chunk) [Company's Key Accounting Data and Financial Indicators](index=6&type=section&id=Company%27s%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In H1 2021, revenue grew **58.02%** to **CNY 600.29 million**, net profit attributable to shareholders increased **78.08%** to **CNY 170.86 million**, and net operating cash flow surged over **12 times**, driven by post-pandemic sales recovery, product line expansion, and significant overseas growth Key Accounting Data for H1 2021 | Key Accounting Data | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :------------------------------------------- | :----------------------- | :----------------------- | :------------- | | Operating Revenue | CNY 600.29 million | CNY 379.87 million | 58.02 | | Net Profit Attributable to Listed Company Shareholders | CNY 170.86 million | CNY 95.94 million | 78.08 | | Net Profit Attributable to Listed Company Shareholders (Excluding Non-Recurring Gains/Losses) | CNY 156.37 million | CNY 85.77 million | 82.32 | | Net Cash Flow from Operating Activities | CNY 122.49 million | CNY 9.37 million | 1,207.62 | | Net Assets Attributable to Listed Company Shareholders (Period-End) | CNY 1.87 billion | CNY 1.84 billion | 1.98 | | Total Assets (Period-End) | CNY 2.75 billion | CNY 2.70 billion | 2.02 | Key Financial Indicators for H1 2021 | Key Financial Indicators | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :------------------------------------------- | :----------------------- | :----------------------- | :----------------------- | | Basic Earnings Per Share (CNY/share) | 0.47 | 0.37 | 27.03 | | Diluted Earnings Per Share (CNY/share) | 0.47 | 0.37 | 27.03 | | Basic Earnings Per Share (Excluding Non-Recurring Gains/Losses) (CNY/share) | 0.43 | 0.33 | 30.30 | | Weighted Average Return on Net Assets (%) | 8.87 | 5.84 | Increased by 3.03 percentage points | | Weighted Average Return on Net Assets (Excluding Non-Recurring Gains/Losses) (%) | 8.12 | 5.22 | Increased by 2.90 percentage points | - During the reporting period, the company's operating revenue increased by **58.02%** year-on-year, primarily due to a lower base in the prior period affected by the COVID-19 pandemic; in the first half of this year, domestic COVID-19 control led to a gradual recovery in domestic sales, while the company's product lines expanded, market development efforts intensified, and various product lines progressed orderly, with significant growth in overseas business[22](index=22&type=chunk) - During the reporting period, the company's net cash flow from operating activities increased by over **12 times** year-on-year, mainly due to active market expansion and orderly progress in product line promotion, leading to a **58.02%** increase in sales, coupled with enhanced control over sales collections and a simultaneous increase in sales prepayments[23](index=23&type=chunk) [Non-Recurring Gains and Losses Items and Amounts](index=7&type=section&id=Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) The company's non-recurring gains and losses totaled **CNY 14.48 million** in H1 2021, primarily from entrusted investment gains, government subsidies, and non-current asset disposal gains Non-Recurring Gains and Losses Items and Amounts for H1 2021 | Non-Recurring Gains and Losses Item | Amount (CNY) | | :------------------------------------------------ | :----------------------- | | Gains or losses from disposal of non-current assets | 171,504.76 | | Government subsidies recognized in current profit or loss | 5,748,565.88 | | Gains or losses from entrusted investment or asset management | 11,414,084.72 | | Other non-operating income and expenses apart from the above | 406,525.23 | | Impact on minority shareholders' equity | -690,451.71 | | Income tax impact | -2,565,433.76 | | **Total** | **14,484,795.12** | Section III Management Discussion and Analysis [Industry and Main Business Overview During the Reporting Period](index=8&type=section&id=Industry%20and%20Main%20Business%20Overview%20During%20the%20Reporting%20Period) The company operates in the in-vitro diagnostics (IVD) industry, focusing on POCT, biochemical, immunoassay, hematology, and coagulation testing, with a comprehensive product line and significant **120.11%** overseas business growth - The company belongs to the 'C27 Pharmaceutical Manufacturing' sub-sector within 'C Manufacturing', specifically the in-vitro diagnostics industry[28](index=28&type=chunk) - The global in-vitro diagnostics market was approximately **USD 52.6 billion** in 2017, projected to reach **USD 79.6 billion** by 2024, with a CAGR of **6.1%**[28](index=28&type=chunk) - In China, immunoassay has surpassed biochemical diagnostics as the largest segment in the in-vitro diagnostics market, holding a **38%** share; molecular diagnostics and POCT are the fastest-growing, with increasing market shares of **15%** and **11%** respectively[30](index=30&type=chunk) - The company has established seven major technology platforms, including colloidal gold immunochromatography, fluorescence immunochromatography, biochemical detection, chemiluminescence immunoassay, molecular diagnostics, calibrator/control development, and diagnostic reagent raw material development, achieving preliminary full industry chain layout[31](index=31&type=chunk) - In H1 2021, the company's overseas business generated **CNY 114 million** in revenue, a year-on-year increase of **120.11%**[32](index=32&type=chunk) - The company provides comprehensive solutions for standardized grassroots laboratories, having served **3** regional testing centers and over **30** medical institutions[36](index=36&type=chunk) [Analysis of Core Competencies During the Reporting Period](index=13&type=section&id=Analysis%20of%20Core%20Competencies%20During%20the%20Reporting%20Period) The company's core competencies include a full industry chain, high raw material self-sufficiency, robust quality system, academic empowerment, extensive domestic and international marketing networks, and a nationwide three-tier after-sales service network - The company's R&D investment in recent years has exceeded **10%** of sales revenue, achieving preliminary full industry chain layout with systematic R&D and production capabilities for instruments, reagents, calibrators, quality controls, and biological raw materials[37](index=37&type=chunk) - The company possesses multiple core technologies, including genetic engineering, monoclonal/polyclonal antibody preparation, and small molecule total synthesis, resulting in a high self-sufficiency rate for raw materials and reduced reliance on imported materials[39](index=39&type=chunk) - The company has established a comprehensive product quality system, consistently passing the National Center for Clinical Laboratories' EQA for many years, and completed international MDSAP quality management system certification in 2020[40](index=40&type=chunk)[41](index=41&type=chunk) - The company has built a comprehensive and multi-dimensional marketing system, offering integrated solutions for chest pain centers, stroke centers, and heart failure centers, while actively participating in various high-end conferences in the domestic and international in-vitro diagnostics field[42](index=42&type=chunk) - As of the end of the reporting period, the company had nearly **1,000** direct channel partners in China, established nearly **ten** subsidiaries in populous provinces like Sichuan, Henan, and Shandong; its overseas market business covers over **110** countries and regions, with **200** direct overseas distributors[42](index=42&type=chunk)[43](index=43&type=chunk)[44](index=44&type=chunk) - The company has established a comprehensive 'Nanjing Headquarters-Regional After-sales Team-Subsidiary After-sales' three-tier after-sales service network, with over **300** direct after-sales service personnel covering national market terminals, aiming for **24-hour** equipment issue resolution[45](index=45&type=chunk) [Discussion and Analysis of Operations](index=15&type=section&id=Discussion%20and%20Analysis%20of%20Operations) In H1 2021, the company achieved **CNY 600 million** in revenue (**58.02%** YoY growth) and **CNY 171 million** in net profit attributable to shareholders (**78.08%** YoY growth), driven by successful new product launches, R&D progress, and significant increases in registered certificates and patents - In H1 2021, the company achieved operating revenue of **CNY 600 million**, a year-on-year increase of **58.02%**; net profit attributable to listed company shareholders was **CNY 171 million**, a year-on-year increase of **78.08%**[47](index=47&type=chunk) - New products such as the Metis600 emergency hematology assembly line, MAGICL6000 compact fully automatic chemiluminescence immunoassay analyzer, and Getein208 portable biochemical immunoassay analyzer were successively launched, completing the strategic layout of the company's POCT product line[48](index=48&type=chunk) - The MAGICL6000 compact fully automatic chemiluminescence immunoassay analyzer targets the mid-to-high-end market, with a maximum speed of **150 tests/hour**, high automation, and support for whole blood sample loading[49](index=49&type=chunk) - During the reporting period, the company submitted **68** new domestic patent applications, held **194** valid authorized domestic patents, **5** international authorized patents, and **65** software copyrights[54](index=54&type=chunk) - In H1 2021, the company obtained a total of **35** product registration certificates (**26** new domestic, **9** EU CE), accumulating **427** product registration certificates, and possessing **803** product entry permits in **41** overseas countries and regions[54](index=54&type=chunk) [Key Operating Performance During the Reporting Period](index=18&type=section&id=Key%20Operating%20Performance%20During%20the%20Reporting%20Period) This section analyzes significant changes in revenue, costs, expenses, and cash flows, along with asset and liability shifts, including decreased trading financial assets, increased receivables and prepayments, and growth in construction in progress and equity investments, also disclosing overseas assets Analysis of Changes in Financial Statement Items | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | Change (%) | | :------------------------------------------- | :----------------------- | :----------------------- | :------------- | | Operating Revenue | 600,288,159.94 | 379,874,328.44 | 58.02 | | Operating Cost | 207,495,136.03 | 131,914,002.63 | 57.30 | | Selling Expenses | 97,269,945.44 | 63,186,294.26 | 53.94 | | Administrative Expenses | 38,818,814.14 | 30,178,791.20 | 28.63 | | Financial Expenses | -3,147,446.70 | -876,118.66 | 259.25 | | Research and Development Expenses | 77,676,327.71 | 52,464,978.60 | 48.05 | | Net Cash Flow from Operating Activities | 122,489,994.89 | 9,367,374.92 | 1,207.62 | | Net Cash Flow from Investing Activities | 109,010,969.85 | -253,122,009.52 | -143.07 | | Net Cash Flow from Financing Activities | -92,566,988.88 | 98,640,724.49 | -193.84 | - The change in operating revenue was primarily due to a lower base in the prior period affected by the COVID-19 pandemic; in H1 this year, domestic COVID-19 control led to a gradual recovery in domestic sales, while the company's product lines expanded, market development efforts intensified, and various product lines progressed orderly, with significant growth in overseas business[58](index=58&type=chunk) - The change in net cash flow from operating activities was mainly due to sales recovery and increased efforts in collecting sales payments during the current period[59](index=59&type=chunk) - The change in net cash flow from investing activities was mainly due to the company's more extensive investment of idle cash, with more redemptions of wealth management products and higher returns compared to the prior period[59](index=59&type=chunk) - The change in net cash flow from financing activities was mainly due to higher bank borrowings in the prior period and partial repayment of bank borrowings in the current period[59](index=59&type=chunk) - Trading financial assets decreased by **34.07%**, primarily due to the redemption of wealth management products[60](index=60&type=chunk)[61](index=61&type=chunk) - Construction in progress increased by **92.40%**, mainly due to increased investment in projects such as the POCT industrial plant Phase II and the plant substation project during the current period[60](index=60&type=chunk)[62](index=62&type=chunk) - Share capital increased by **39.76%**, primarily due to the company's 2020 annual profit distribution, involving a capital reserve transfer to share capital during the current period[61](index=61&type=chunk)[62](index=62&type=chunk) - Overseas assets totaled **CNY 321,764.79**, accounting for **0.012%** of total assets, all belonging to the subsidiary Getian Bio-Tech (USA) Co., Ltd[64](index=64&type=chunk) [Investment Status Analysis](index=21&type=section&id=Investment%20Status%20Analysis) The company established Zhejiang Jizhongkang Biomedical Co., Ltd. to expand sales channels; as of the reporting period end, **CNY 392.20 million** in wealth management products remained outstanding, incurring a fair value change loss of **CNY 5.83 million**, with detailed financial data for major subsidiaries - The company established Zhejiang Jizhongkang Biomedical Co., Ltd., a controlled subsidiary in Hangzhou, primarily as a sales platform for Getian Bio and other medical device products[68](index=68&type=chunk) - As of the end of the reporting period, the company's outstanding wealth management products amounted to **CNY 392.20 million**, resulting in a fair value change loss of **CNY 5.83 million** for the current period[69](index=69&type=chunk) Financial Data of Major Controlled and Invested Companies (Unit: CNY 10,000) | Subsidiary Name | Registered Capital | Total Assets | Net Assets | Operating Revenue | Net Profit | Main Business | | :------------------------------------------- | :----------------- | :----------- | :----------- | :---------------- | :--------- | :---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- [Key Accounting Data for H1 2021](index=6&type=section&id=Company%27s%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company's operating revenue for the current period was **CNY 600.29 million**, a **58.02%** increase from the prior period. Net profit attributable to listed company shareholders was **CNY 170.86 million**, up **78.08%**. Net cash flow from operating activities saw a significant increase of **1,207.62%** to **CNY 122.49 million**. Total assets at period-end reached **CNY 2.75 billion**, a **2.02%** increase. Key Accounting Data for H1 2021 | Key Accounting Data | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :------------------------------------------- | :----------------------- | :----------------------- | :------------- | | Operating Revenue | 600,288,159.94 | 379,874,328.44 | 58.02 | | Net Profit Attributable to Listed Company Shareholders | 170,856,236.75 | 95,941,887.75 | 78.08 | | Net Profit Attributable to Listed Company Shareholders (Excluding Non-Recurring Gains/Losses) | 156,371,441.63 | 85,767,654.80 | 82.32 | | Net Cash Flow from Operating Activities | 122,489,994.89 | 9,367,374.92 | 1,207.62 | | Net Assets Attributable to Listed Company Shareholders (Period-End) | 1,874,431,297.90 | 1,837,985,536.40 | 1.98 | | Total Assets (Period-End) | 2,754,401,646.99 | 2,699,983,947.97 | 2.02 | Key Financial Indicators for H1 2021 | Key Financial Indicators | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :------------------------------------------- | :----------------------- | :----------------------- | :----------------------- | | Basic Earnings Per Share (CNY/share) | 0.47 | 0.37 | 27.03 | | Diluted Earnings Per Share (CNY/share) | 0.47 | 0.37 | 27.03 | | Basic Earnings Per Share (Excluding Non-Recurring Gains/Losses) (CNY/share) | 0.43 | 0.33 | 30.30 | | Weighted Average Return on Net Assets (%) | 8.87 | 5.84 | Increased by 3.03 percentage points | | Weighted Average Return on Net Assets (Excluding Non-Recurring Gains/Losses) (%) | 8.12 | 5.22 | Increased by 2.90 percentage points | - During the reporting period, the company's operating revenue increased by **58.02%** year-on-year, primarily due to a lower base in the prior period affected by the COVID-19 pandemic; in the first half of this year, domestic COVID-19 control led to a gradual recovery in domestic sales, while the company's product lines expanded, market development efforts intensified, and various product lines progressed orderly, with significant growth in overseas business[22](index=22&type=chunk) - During the reporting period, the company's net cash flow from operating activities increased by over **12 times** year-on-year, mainly due to active market expansion and orderly progress in product line promotion, leading to a **58.02%** increase in sales, coupled with enhanced control over sales collections and a simultaneous increase in sales prepayments[23](index=23&type=chunk) [Non-Recurring Gains and Losses Items and Amounts](index=7&type=section&id=Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) The company's non-recurring gains and losses totaled **CNY 14.48 million** in H1 2021, primarily from entrusted investment gains, government subsidies, and non-current asset disposal gains Non-Recurring Gains and Losses Items and Amounts for H1 2021 | Non-Recurring Gains and Losses Item | Amount (CNY) | | :------------------------------------------------ | :----------------------- | | Gains or losses from disposal of non-current assets | 171,504.76 | | Government subsidies recognized in current profit or loss | 5,748,565.88 | | Gains or losses from entrusted investment or asset management | 11,414,084.72 | | Other non-operating income and expenses apart from the above | 406,525.23 | | Impact on minority shareholders' equity | -690,451.71 | | Income tax impact | -2,565,433.76 | | **Total** | **14,484,795.12** | Section III Management Discussion and Analysis [Industry and Main Business Overview During the Reporting Period](index=8&type=section&id=Industry%20and%20Main%20Business%20Overview%20During%20the%20Reporting%20Period) The company operates in the in-vitro diagnostics (IVD) industry, focusing on POCT, biochemical, immunoassay, hematology, and coagulation testing, with a comprehensive product line and significant **120.11%** overseas business growth - The company belongs to the 'C27 Pharmaceutical Manufacturing' sub-sector within 'C Manufacturing', specifically the in-vitro diagnostics industry[28](index=28&type=chunk) - The global in-vitro diagnostics market was approximately **USD 52.6 billion** in 2017, projected to reach **USD 79.6 billion** by 2024, with a CAGR of **6.1%**[28](index=28&type=chunk) - In China, immunoassay has surpassed biochemical diagnostics as the largest segment in the in-vitro diagnostics market, holding a **38%** share; molecular diagnostics and POCT are the fastest-growing, with increasing market shares of **15%** and **11%** respectively[30](index=30&type=chunk) - The company has established seven major technology platforms, including colloidal gold immunochromatography, fluorescence immunochromatography, biochemical detection, chemiluminescence immunoassay, molecular diagnostics, calibrator/control development, and diagnostic reagent raw material development, achieving preliminary full industry chain layout[31](index=31&type=chunk) - In H1 2021, the company's overseas business generated **CNY 114 million** in revenue, a year-on-year increase of **120.11%**[32](index=32&type=chunk) - The company provides comprehensive solutions for standardized grassroots laboratories, having served **3** regional testing centers and over **30** medical institutions[36](index=36&type=chunk) [Analysis of Core Competencies During the Reporting Period](index=13&type=section&id=Analysis%20of%20Core%20Competencies%20During%20the%20Reporting%20Period) The company's core competencies include a full industry chain, high raw material self-sufficiency, robust quality system, academic empowerment, extensive domestic and international marketing networks, and a nationwide three-tier after-sales service network - The company's R&D investment in recent years has exceeded **10%** of sales revenue, achieving preliminary full industry chain layout with systematic R&D and production capabilities for instruments, reagents, calibrators, quality controls, and biological raw materials[37](index=37&type=chunk) - The company possesses multiple core technologies, including genetic engineering, monoclonal/polyclonal antibody preparation, and small molecule total synthesis, resulting in a high self-sufficiency rate for raw materials and reduced reliance on imported materials[39](index=39&type=chunk) - The company has established a comprehensive product quality system, consistently passing the National Center for Clinical Laboratories' EQA for many years, and completed international MDSAP quality management system certification in 2020[40](index=40&type=chunk)[41](index=41&type=chunk) - The company has built a comprehensive and multi-dimensional marketing system, offering integrated solutions for chest pain centers, stroke centers, and heart failure centers, while actively participating in various high-end conferences in the domestic and international in-vitro diagnostics field[42](index=42&type=chunk) - As of the end of the reporting period, the company had nearly **1,000** direct channel partners in China, established nearly **ten** subsidiaries in populous provinces like Sichuan, Henan, and Shandong; its overseas market business covers over **110** countries and regions, with **200** direct overseas distributors[42](index=42&type=chunk)[43](index=43&type=chunk)[44](index=44&type=chunk) - The company has established a comprehensive 'Nanjing Headquarters-Regional After-sales Team-Subsidiary After-sales' three-tier after-sales service network, with over **300** direct after-sales service personnel covering national market terminals, aiming for **24-hour** equipment issue resolution[45](index=45&type=chunk) [Discussion and Analysis of Operations](index=15&type=section&id=Discussion%20and%20Analysis%20of%20Operations) In H1 2021, the company achieved **CNY 600 million** in revenue (**58.02%** YoY growth) and **CNY 171 million** in net profit attributable to shareholders (**78.08%** YoY growth), driven by successful new product launches, R&D progress, and significant increases in registered certificates and patents - In H1 2021, the company achieved operating revenue of **CNY 600 million**, a year-on-year increase of **58.02%**; net profit attributable to listed company shareholders was **CNY 171 million**, a year-on-year increase of **78.08%**[47](index=47&type=chunk) - New products such as the Metis600 emergency hematology assembly line, MAGICL6000 compact fully automatic chemiluminescence immunoassay analyzer, and Getein208 portable biochemical immunoassay analyzer were successively launched, completing the strategic layout of the company's POCT product line[48](index=48&type=chunk) - The MAGICL6000 compact fully automatic chemiluminescence immunoassay analyzer targets the mid-to-high-end market, with a maximum speed of **150 tests/hour**, high automation, and support for whole blood sample loading[49](index=49&type=chunk) - During the reporting period, the company submitted **68** new domestic patent applications, held **194** valid authorized domestic patents, **5** international authorized patents, and **65** software copyrights[54](index=54&type=chunk) - In H1 2021, the company obtained a total of **35** product registration certificates (**26** new domestic, **9** EU CE), accumulating **427** product registration certificates, and possessing **803** product entry permits in **41** overseas countries and regions[54](index=54&type=chunk) [Key Operating Performance During the Reporting Period](index=18&type=section&id=Key%20Operating%20Performance%20During%20the%20Reporting%20Period) This section analyzes significant changes in revenue, costs, expenses, and cash flows, along with asset and liability shifts, including decreased trading financial assets, increased receivables and prepayments, and growth in construction in progress and equity investments, also disclosing overseas assets Analysis of Changes in Financial Statement Items | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | Change (%) | | :------------------------------------------- | :----------------------- | :----------------------- | :------------- | | Operating Revenue | 600,288,159.94 | 379,874,328.44 | 58.02 | | Operating Cost | 207,495,136.03 | 131,914,002.63 | 57.30 | | Selling Expenses | 97,269,945.44 | 63,186,294.26 | 53.94 | | Administrative Expenses | 38,818,814.14 | 30,178,791.20 | 28.63 | | Financial Expenses | -3,147,446.70 | -876,118.66 | 259.25 | | Research and Development Expenses | 77,676,327.71 | 52,464,978.60 | 48.05 | | Net Cash Flow from Operating Activities | 122,489,994.89 | 9,367,374.92 | 1,207.62 | | Net Cash Flow from Investing Activities | 109,010,969.85 | -253,122,009.52 | -143.07 | | Net Cash Flow from Financing Activities | -92,566,988.88 | 98,640,724.49 | -193.84 | - The change in operating revenue was primarily due to a lower base in the prior period affected by the COVID-19 pandemic; in H1 this year, domestic COVID-19 control led to a gradual recovery in domestic sales, while the company's product lines expanded, market development efforts intensified, and various product lines progressed orderly, with significant growth in overseas business[58](index=58&type=chunk) - The change in net cash flow from operating activities was mainly due to sales recovery and increased efforts in collecting sales payments during the current period[59](index=59&type=chunk) - The change in net cash flow from investing activities was mainly due to the company's more extensive investment of idle cash, with more redemptions of wealth management products and higher returns compared to the prior period[59](index=59&type=chunk) - The change in net cash flow from financing activities was mainly due to higher bank borrowings in the prior period and partial repayment of bank borrowings in the current period[59](index=59&type=chunk) - Trading financial assets decreased by **34.07%**, primarily due to the redemption of wealth management products[60](index=60&type=chunk)[61](index=61&type=chunk) - Construction in progress increased by **92.40%**, mainly due to increased investment in projects such as the POCT industrial plant Phase II and the plant substation project during the current period[60](index=60&type=chunk)[62](index=62&type=chunk) - Share capital increased by **39.76%**, primarily due to the company's 2020 annual profit distribution, involving a capital reserve transfer to share capital during the current period[61](index=61&type=chunk)[62](index=62&type=chunk) - Overseas assets totaled **CNY 321,764.79**, accounting for **0.012%** of total assets, all belonging to the subsidiary Getian Bio-Tech (USA) Co., Ltd[64](index=64&type=chunk) [Investment Status Analysis](index=21&type=section&id=Investment%20Status%20Analysis) The company established Zhejiang Jizhongkang Biomedical Co., Ltd. to expand sales channels; as of the reporting period end, **CNY 392.20 million** in wealth management products remained outstanding, incurring a fair value change loss of **CNY 5.83 million**, with detailed financial data for major subsidiaries - The company established Zhejiang Jizhongkang Biomedical Co., Ltd., a controlled subsidiary in Hangzhou, primarily as a sales platform for Getian Bio and other medical device products[68](index=68&type=chunk) - As of the end of the reporting period, the company's outstanding wealth management products amounted to **CNY 392.20 million**, resulting in a fair value change loss of **CNY 5.83 million** for the current period[69](index=69&type=chunk) Financial Data of Major Controlled and Invested Companies (Unit: CNY 10,000) | Subsidiary Name | Registered Capital | Total Assets | Net Assets | Operating Revenue | Net Profit | Main Business | | :------------------------------------------- | :----------------- | :----------- | :----------- | :---------------- | :--------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

公司代码：603387 公司简称：基蛋生物 基蛋生物科技股份有限公司 2020 年年度报告 二零二一年四月 中国 南京 基蛋生物 2020 年年度报告 重要提示 三、 中天运会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人苏恩本、主管会计工作负责人倪文及会计机构负责人（会计主管人员）倪文声 明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司2020年度利润分配预案如下：拟以实施权益分派股权登记日总股本数扣除回购专户内已 回购股份后的股本为基数(具体日期将在权益分派实施公告中明确,在实施权益分派的股权登记 日前公司总股本、回购专户内已回购股份数发生变动的，拟维持分配总额不变，相应调整每股分 配比例)，向全体股东每10股派发人民币3.6元（含税），同时以资本公积向全体股东每10股转增 4股，剩余未分配利润结转以后年度分配；以2021年4月20日的总股本26,034.0871万股扣除回购 专户上已回购股份156.0790万股进行计算，公司共需派发现金股利9,316.082916万元，转增股本 10,351.2032万 ...

[Important Notice](index=3&type=section&id=%E4%B8%80%E3%80%81%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) The company's board of directors, supervisory board, and all directors, supervisors, and senior management guarantee the truthfulness, accuracy, and completeness of this quarterly report - The company's responsible person, the person in charge of accounting work, and the head of the accounting department guarantee the truthfulness, accuracy, and completeness of the financial statements in the quarterly report[5](index=5&type=chunk) - This company's third-quarter report is unaudited[5](index=5&type=chunk) [Company Profile](index=3&type=section&id=%E4%BA%8C%E3%80%81%20%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) This section provides an overview of the company's fundamental information, including key financial data and shareholder structure [Key Financial Data](index=3&type=section&id=2.1%20%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE) In the first three quarters of 2020, operating revenue grew **20.99%** to **763 million RMB**, while net profit attributable to shareholders slightly decreased **0.88%** to **197 million RMB**, with operating cash flow increasing **46.77%** and total assets growing **20.49%** 2020 First Three Quarters Key Financial Data | Indicator | Year-to-Date (Jan-Sep) | Prior Year-to-Date (Jan-Sep) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 762,903,602.56 RMB | 630,555,259.90 RMB | 20.99% | | Net Profit Attributable to Shareholders | 197,122,874.26 RMB | 198,868,020.86 RMB | -0.88% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | 176,680,757.42 RMB | 172,132,565.92 RMB | 2.64% | | Net Cash Flow from Operating Activities | 81,699,213.96 RMB | 55,665,345.52 RMB | 46.77% | | Basic Earnings Per Share (RMB/share) | 0.75 | 0.77 | -2.60% | | **Indicator** | **As of Report Period End** | **As of Prior Year-End** | **Change (%)** | | Total Assets | 2,418,944,330.76 RMB | 2,007,639,351.37 RMB | 20.49% | | Net Assets Attributable to Shareholders | 1,729,578,524.02 RMB | 1,624,972,044.14 RMB | 6.44% | 2020 First Three Quarters Non-recurring Gains and Losses | Item | Year-to-Date Amount (Jan-Sep) | | :--- | :--- | | Gains/Losses from Disposal of Non-current Assets | 470,895.59 RMB | | Government Grants Included in Current Profit/Loss | 12,071,246.22 RMB | | Gains/Losses from Entrusted Investment or Asset Management | 14,577,660.45 RMB | | Other Non-operating Income and Expenses, Net | -3,802,228.53 RMB | | **Total** | **20,442,116.84 RMB** | [Shareholder Information](index=4&type=section&id=2.2%20%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) As of September 30, 2020, the company had **18,398** shareholders, with controlling shareholder Su Enben holding **39.52%** and having related party relationships with Su Enkui and Nanjing Aiji Information Consulting Co., Ltd - As of the end of the reporting period, the company had a total of **18,398** shareholders[8](index=8&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shares Held at Period End | Percentage (%) | | :--- | :--- | :--- | | Su Enben | 102,893,008 | 39.52 | | Nanjing Aiji Information Consulting Co., Ltd. | 11,336,399 | 4.35 | | National Council for Social Security Fund 503 Portfolio | 9,000,045 | 3.46 | | Huatai Zijin (Jiangsu) Equity Investment Fund | 7,454,241 | 2.86 | | Xu Xingde | 5,938,953 | 2.28 | | Hong Kong Securities Clearing Company Limited | 5,642,243 | 2.17 | | Tianjin Jieyuan Asset Management Partnership | 3,764,376 | 1.45 | | Su Enkui | 3,011,501 | 1.16 | | Dongxing Securities Co., Ltd. | 2,885,421 | 1.11 | | Bank of China - China Merchants CSI Bio-Pharmaceutical Index Graded Fund | 2,287,949 | 0.88 | - Explanation of major shareholder related party relationships: Su Enben and Su Enkui are brothers, and Su Enben is the actual controller of Nanjing Aiji Information Consulting Co., Ltd[10](index=10&type=chunk) [Preferred Shareholder Information](index=6&type=section&id=2.3%20%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) The company had no preferred shareholders during the reporting period - The company has no preferred shareholders[11](index=11&type=chunk) [Significant Events](index=6&type=section&id=%E4%B8%89%E3%80%81%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section details significant events, including major changes in financial statement items, progress of key initiatives, and fulfillment of commitments [Analysis of Significant Changes in Key Financial Statement Items and Indicators](index=6&type=section&id=3.1%20%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%8A%A5%E8%A1%A8%E9%A1%B9%E7%9B%AE%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87%E9%87%8D%E5%A4%A7%E5%8F%98%E5%8A%A8%E7%9A%84%E6%83%85%E5%86%B5%E5%8F%8A%E5%8E%9F%E5%9B%A0) Significant changes occurred across financial accounts, with accounts receivable up **79.86%** due to agency business, construction in progress up **211.92%**, short-term borrowings up **211.82%**, operating costs up **55.63%** from higher-cost agency business, and increased net cash outflow from investing activities due to wealth management product purchases Balance Sheet and Income Statement Major Changes | Account Name | Change Ratio (%) | Primary Reason | | :--- | :--- | :--- | | Accounts Receivable | 79.86% | Increase in terminal hospital payments due to increased agency business | | Construction in Progress | 211.92% | New equipment awaiting installation and expenditures for Phase II factory construction | | Development Expenditures | 578.08% | Increased investment in development expenditures during the reporting period | | Goodwill | 8,348.96% | New consolidation of controlling subsidiary Jingchuan Diagnostics | | Short-term Borrowings | 211.82% | Increased short-term borrowings due to reasonable utilization of bank credit lines | | Operating Costs | 55.63% | Change in revenue structure, with an increase in higher-cost agency business | | Financial Expenses | -362.95% | Combined impact of new loan interest expenses and changes in exchange gains/losses | | Credit Impairment Losses | 124.66% | Increase in accounts receivable led to a corresponding increase in credit impairment losses | Cash Flow Statement Major Changes | Project Name | Change Ratio (%) | Primary Reason | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 46.77% | Increase in sales collections and decrease in taxes paid | | Net Cash Flow from Investing Activities | -470.37% | Increase in amounts paid for wealth management products during the current period | | Net Cash Flow from Financing Activities | -277.77% | Increase in loans obtained during the current period | [Progress of Significant Events](index=8&type=section&id=3.2%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9%E8%BF%9B%E5%B1%95%E6%83%85%E5%86%B5%E5%8F%8A%E5%85%B6%E5%BD%B1%E5%93%8D%E5%92%8C%E8%A7%A3%E5%86%B3%E6%96%B9%E6%A1%88%E7%9A%84%E5%88%86%E6%9E%90%E8%AF%B4%E6%98%8E) During the reporting period, the company actively managed idle funds, with **528.15 million RMB** in outstanding wealth management products and **12.37 million RMB** in cumulative income, and successfully acquired **54.96%** of Wuhan Jingchuan Diagnostics Technology Co., Ltd., making it a controlling subsidiary - The company utilized idle self-owned funds not exceeding **1.5 billion RMB** for cash management; as of September 30, 2020, the outstanding balance of wealth management products was **528.15 million RMB**, generating cumulative income of **12.37 million RMB** during the reporting period[16](index=16&type=chunk) - The company completed the share acquisition and capital increase of Wuhan Jingchuan Diagnostics Technology Co., Ltd., holding a total of **54.96%** of its shares, making Jingchuan Diagnostics a controlling subsidiary[17](index=17&type=chunk) [Fulfillment of Commitments](index=9&type=section&id=3.3%20%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E8%B6%85%E6%9C%9F%E6%9C%AA%E5%B1%A5%E8%A1%8C%E5%AE%8C%E6%AF%95%E7%9A%84%E6%89%BF%E8%AF%BA%E4%BA%8B%E9%A1%B9) The company had no overdue unfulfilled commitments during the reporting period - The company had no overdue unfulfilled commitments during the reporting period[19](index=19&type=chunk) [Performance Forecast](index=9&type=section&id=3.4%20%E9%A2%84%E6%B5%8B%E5%B9%B4%E5%88%9D%E8%87%B3%E4%B8%8B%E4%B8%80%E6%8A%A5%E5%91%8A%E6%9C%9F%E6%9C%9F%E6%9C%AB%E7%9A%84%E7%B4%AF%E8%AE%A1%E5%87%80%E5%88%A9%E6%B6%A6%E5%8F%AF%E8%83%BD%E4%B8%BA%E4%BA%8F%E6%8D%9F%E6%88%96%E4%B8%8E%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E7%9B%B8%E6%AF%94%E5%8F%91%E7%94%9F%E9%87%8D%E5%A4%A7%E5%8F%98%E5%8A%A8%E7%9A%84%E8%AD%A6%E7%A4%BA%E5%8F%8A%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The company has not issued any warnings regarding potential cumulative net profit losses or significant changes from the beginning of the year to the end of the next reporting period - The company has not predicted that the cumulative net profit from the beginning of the year to the end of the next reporting period may be a loss or undergo significant changes compared to the same period last year[19](index=19&type=chunk) [Appendix](index=10&type=section&id=%E5%9B%9B%E3%80%81%20%E9%99%84%E5%BD%95) This section contains the company's financial statements and related disclosures [Financial Statements](index=10&type=section&id=4.1%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section provides the company's consolidated and parent company balance sheets, income statements, and cash flow statements as of September 30, 2020 [Consolidated Balance Sheet](index=10&type=section&id=%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of September 30, 2020, the company's total assets were **2.42 billion RMB**, up **20.49%** from the beginning of the year; total liabilities were **534 million RMB**, up **63.76%**; and equity attributable to parent company owners was **1.73 billion RMB**, up **6.44%** [Company Balance Sheet](index=12&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of September 30, 2020, the parent company's total assets were **2.09 billion RMB**, total liabilities were **415 million RMB**, and total owner's equity was **1.67 billion RMB** [Consolidated Income Statement](index=14&type=section&id=%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) In the first three quarters of 2020, the company achieved total operating revenue of **763 million RMB**, up **20.99%**; total operating costs of **534 million RMB**, up **25.62%**; and net profit attributable to parent company shareholders of **197 million RMB**, down **0.88%**, with Q3 net profit attributable to parent company shareholders at **101 million RMB**, up **124.78%** [Company Income Statement](index=17&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E5%88%A9%E6%B6%A6%E8%A1%A8) In the first three quarters of 2020, the parent company achieved operating revenue of **401 million RMB**, down **12.39%**, and net profit of **136 million RMB**, down **36.90%** [Consolidated Cash Flow Statement](index=20&type=section&id=%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) In the first three quarters of 2020, net cash flow from operating activities was **81.70 million RMB**, up **46.77%**; net cash flow from investing activities was **-177 million RMB** due to increased investment payments; and net cash flow from financing activities was **103 million RMB** due to increased borrowings [Company Cash Flow Statement](index=21&type=section&id=%E6%AF%8D%E5%85%AC%E5%8F%B8%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) In the first three quarters of 2020, the parent company's net cash flow from operating activities was **126 million RMB**, up **15.49%**; net cash flow from investing activities was **-273 million RMB**; and net cash flow from financing activities was **67.20 million RMB** [Explanation of Adjustments for First-Time Adoption of New Standards](index=22&type=section&id=4.2%202020%20%E5%B9%B4%E8%B5%B7%E9%A6%96%E6%AC%A1%E6%89%A7%E8%A1%8C%E6%96%B0%E6%94%B6%E5%85%A5%E5%87%86%E5%88%99%E3%80%81%E6%96%B0%E7%A7%9F%E8%B5%81%E5%87%86%E5%88%99%E8%B0%83%E6%95%B4%E9%A6%96%E6%AC%A1%E6%89%A7%E8%A1%8C%E5%BD%93%E5%B9%B4%E5%B9%B4%E5%88%9D%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) Effective January 1, 2020, the company adopted new revenue standards, reclassifying advance receipts from 'Advance Receipts' to 'Contract Liabilities,' which only impacts financial statement presentation without affecting opening total assets, total liabilities, or net assets - The company adopted the new revenue standard effective January 1, 2020[47](index=47&type=chunk)[51](index=51&type=chunk) Consolidated Balance Sheet Adjustments | Item | December 31, 2019 | January 1, 2020 | Adjustment Amount | | :--- | :--- | :--- | :--- | | Advance Receipts | 39,686,835.91 RMB | 0 RMB | -39,686,835.91 RMB | | Contract Liabilities | 0 RMB | 39,686,835.91 RMB | 39,686,835.91 RMB | [Audit Report](index=27&type=section&id=4.4%20%E5%AE%A1%E8%AE%A1%E6%8A%A5%E5%91%8A) This quarterly report is unaudited - This quarterly financial report is unaudited[52](index=52&type=chunk)

公司代码：603387 公司简称：基蛋生物 基蛋生物科技股份有限公司 2020 年半年度报告 二零二零年八月 中国 南京 基蛋生物 2020 年半年度报告 重要提示 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 公司已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险及应对措施，敬请查阅第 四节"经营情况讨论与分析"之"可能面对的风险"。敬请投资者注意投资风险。 十、 其他 □适用 √不适用 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人苏恩本、主管会计工作负责人倪文 及会计机构负责人（会计主管人员）倪文声 明： ...

[Important Notice](index=3&type=section&id=Item%20I.%20Important%20Notice) The board, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, which remains unaudited - The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report content and assume legal responsibility[6](index=6&type=chunk) - All directors attended the board meeting to review the quarterly report[6](index=6&type=chunk) - This first quarter report is unaudited[6](index=6&type=chunk) [Company Profile](index=3&type=section&id=Item%20II.%20Company%20Profile) This section provides an overview of the company's key financial data and shareholder information as of the reporting period [Key Financial Data](index=3&type=section&id=2.1%20Key%20Financial%20Data) At the end of the reporting period, the company's total assets increased by 11.27% year-on-year, and net assets attributable to shareholders increased by 2.70%; however, due to the pandemic, operating revenue and net profit attributable to shareholders decreased by 28.27% and 49.12% respectively, with net cash flow from operating activities significantly declining by 459.01% Overview of Key Financial Data (As of March 31, 2020) | Indicator | Current Period End (Yuan) | Previous Year End (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 2,233,890,370.80 | 2,007,639,351.37 | 11.27 | | Net Assets Attributable to Shareholders of Listed Company | 1,668,849,332.05 | 1,624,972,044.14 | 2.70 | | Indicator | Year-to-Date (Yuan) | Previous Year-to-Date (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -46,904,908.02 | -8,390,655.20 | 459.01 | | Operating Revenue | 148,162,241.23 | 206,565,571.46 | -28.27 | | Net Profit Attributable to Shareholders of Listed Company | 43,247,242.43 | 84,999,724.84 | -49.12 | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Items) | 36,232,783.46 | 66,001,470.56 | -45.10 | | Weighted Average Return on Net Assets (%) | 2.63 | 6.12 | Decrease by 57.12 percentage points | | Basic Earnings Per Share (Yuan/share) | 0.12 | 0.23 | -47.83 | | Diluted Earnings Per Share (Yuan/share) | 0.12 | 0.23 | -47.83 | Non-Recurring Gains and Losses (Current Period) | Item | Current Period Amount (Yuan) | | :--- | :--- | | Gains or losses from disposal of non-current assets | -372,038.29 | | Government grants recognized in current profit or loss | 3,195,571.58 | | Gains or losses from entrusted investment or asset management | 4,803,985.72 | | Gains or losses from changes in fair value and investment income from disposal of financial assets | 1,005,198.56 | | Other non-operating income and expenses | -384,884.52 | | Impact on minority interests (after tax) | 1,916.17 | | Income tax impact | -1,235,290.25 | | Total | 7,014,458.97 | [Shareholder Ownership](index=4&type=section&id=2.2%20Total%20Number%20of%20Shareholders%2C%20Top%20Ten%20Shareholders%2C%20and%20Top%20Ten%20Circulating%20Shareholders%20(or%20Unrestricted%20Shareholders)%20as%20of%20the%20End%20of%20the%20Reporting%20Period) As of the end of the reporting period, the company had 19,521 shareholders, with Su Enben holding the largest stake among the top ten at 39.52%, with some shares pledged, and the report also disclosed the top ten unrestricted circulating shareholders and their affiliations - As of the end of the reporting period, the total number of shareholders was **19,521**[9](index=9&type=chunk) Top Ten Shareholders' Holdings (As of March 31, 2020) | Shareholder Name | Shares Held at Period End (10,000 shares) | Percentage (%) | Restricted Shares Held (10,000 shares) | Share Status | Pledged or Frozen Shares (10,000 shares) | Shareholder Nature | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Su Enben | 10,289.3008 | 39.52 | 10,289.3008 | Pledged | 1,552.40 | Domestic Natural Person | | Nanjing Aiji Information Consulting Co., Ltd. | 1,133.6399 | 4.35 | 1,133.6399 | Unrestricted | | Domestic Non-State Legal Person | | Suzhou Jiefu Investment Enterprise (Limited Partnership) | 983.0048 | 3.78 | 0 | Unrestricted | | Domestic Non-State Legal Person | | Huatai Zijin (Jiangsu) Equity Investment Fund (Limited Partnership) | 745.4241 | 2.86 | 745.4241 | Unrestricted | | Domestic Non-State Legal Person | | Hangzhou Weisijielang Equity Investment Partnership (Limited Partnership) | 708.8859 | 2.72 | 0 | Unrestricted | | Domestic Non-State Legal Person | | Xu Xingde | 623.8857 | 2.40 | 0 | Unrestricted | | Domestic Natural Person | | Tianjin Jieyuan Asset Management Partnership (Limited Partnership) | 376.4376 | 1.45 | 376.4376 | Unrestricted | | Domestic Non-State Legal Person | | Su Enkui | 301.1501 | 1.16 | 301.1501 | Unrestricted | | Domestic Natural Person | | Hong Kong Securities Clearing Company Limited | 273.4145 | 1.05 | 0 | Unrestricted | | Overseas Legal Person | | Fei Wan'e | 148.1916 | 0.57 | 0 | Unrestricted | | Domestic Natural Person | - Su Enben, Su Enkui, and Nanjing Aiji Information Consulting Co., Ltd. have an affiliated relationship, with Su Enben being the actual controller of Nanjing Aiji Information Consulting Co., Ltd[10](index=10&type=chunk) [Preferred Shareholder Ownership](index=5&type=section&id=2.3%20Total%20Number%20of%20Preferred%20Shareholders%2C%20Top%20Ten%20Preferred%20Shareholders%2C%20and%20Top%20Ten%20Unrestricted%20Preferred%20Shareholders%20as%20of%20the%20End%20of%20the%20Reporting%20Period) The company had no preferred shareholder ownership at the end of the reporting period, rendering this section not applicable - There were no preferred shareholder holdings at the end of the reporting period[11](index=11&type=chunk) [Significant Events](index=5&type=section&id=Item%20III.%20Significant%20Events) This section details significant changes in key financial items, progress on important matters, and any unfulfilled commitments during the reporting period [Major Changes and Reasons for Key Financial Statement Items](index=5&type=section&id=3.1%20Major%20Changes%20and%20Reasons%20for%20Key%20Financial%20Statement%20Items%20and%20Financial%20Indicators) During the reporting period, several financial accounts experienced significant changes, with cash and cash equivalents increasing by **47.54%** due to increased bank borrowings and redemption of wealth management products, and short-term borrowings rising by **230.11%** for future development; however, operating revenue, net profit, selling expenses, other income, and investment income all significantly decreased due to the pandemic, and net cash flow from operating activities sharply declined by **459.01%** due to reduced business volume and increased procurement expenses Changes in Key Financial Statement Items (Current Period End vs. Previous Year End) | Account Name | Current Period End (Yuan) | Previous Year End (Yuan) | Change (%) | Remarks | | :--- | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 973,020,839.43 | 659,479,188.58 | 47.54 | Increase in bank borrowings and redemption of wealth management products | | Trading Financial Assets | 317,142,481.48 | 467,355,257.91 | -32.14 | Maturity and redemption of wealth management products | | Notes Receivable | 1,229,765.60 | 9,077,711.80 | -86.45 | Notes collected upon maturity | | Advance Payments | 24,823,086.01 | 18,299,031.23 | 35.65 | Increase in advance payments for materials | | Other Receivables | 17,382,248.78 | 10,860,085.59 | 60.06 | Increase in intercompany receivables | | Construction in Progress | 23,647,033.28 | 11,602,255.48 | 103.81 | New equipment awaiting installation and Phase II factory construction expenses | | Short-term Borrowings | 313,600,000.00 | 95,000,000.00 | 230.11 | Rational utilization of bank credit lines, new borrowings | | Advance Receipts | - | 39,686,835.91 | -100.00 | Reclassified to contract liabilities | | Employee Benefits Payable | 13,922,739.31 | 39,240,786.13 | -64.52 | Year-end bonuses have been paid | | Taxes Payable | 10,013,736.71 | 23,108,789.04 | -56.67 | Previous year-end included Q4 taxes, paid in current period | | Contract Liabilities | 42,765,718.76 | - | 100.00 | Reclassification under new revenue standard | | Provisions | 1,108,819.61 | 1,758,923.77 | -36.96 | Decrease due to consumption in current period | Changes in Key Income Statement and Cash Flow Statement Items (Current Period vs. Previous Period) | Item Name | Current Period Amount (Yuan) | Previous Period Amount (Yuan) | Change (%) | Remarks | | :--- | :--- | :--- | :--- | :--- | | Selling Expenses | 23,306,597.32 | 35,204,355.49 | -33.80 | Restricted sales activities during the pandemic | | Financial Expenses | -6,090,218.54 | 516,478.62 | -1,279.18 | Increase in time deposits, increase in interest income | | Credit Impairment Losses and Asset Impairment Losses | 1,324,492.12 | -326,136.84 | -506.12 | Increase in accounts receivable, increase in credit impairment losses | | Other Income | 3,261,624.04 | 9,450,506.54 | -65.49 | Decrease in government subsidies | | Investment Income | 4,434,210.86 | 7,635,173.32 | -41.92 | Decrease in purchases of wealth management products | | Gains on Asset Disposal | 210,900.58 | 28,740.58 | 633.81 | Increase in asset disposals | | Non-Operating Expenses | 626,806.43 | 96,274.37 | 551.06 | Donation expenses during the pandemic | | Income Tax Expense | 6,197,621.92 | 11,255,444.03 | -44.94 | Decrease in profit led to decrease in income tax | | Net Cash Flow from Operating Activities | -46,904,908.02 | -8,390,655.20 | 459.01 | Pandemic impact, reduced business volume, increased procurement expenses | | Net Cash Flow from Investing Activities | 153,921,032.70 | 13,765,986.12 | 1,018.13 | Increase in redemption amount of wealth management products | | Net Cash Flow from Financing Activities | 209,096,477.22 | -4,187,359.60 | -5,093.52 | Increase in borrowings | | Net Profit Attributable to Shareholders of Listed Company | 43,247,242.43 | 84,999,724.84 | -49.12 | Pandemic impact, decrease in performance | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Items) | 36,232,783.46 | 66,001,470.56 | -45.10 | Pandemic impact, decrease in performance | | Weighted Average Return on Net Assets (%) | 2.63 | 6.12 | -57.12 | Pandemic impact, decrease in performance | | Basic Earnings Per Share (Yuan/share) | 0.12 | 0.23 | -47.83 | Pandemic impact, decrease in performance | | Diluted Earnings Per Share (Yuan/share) | 0.12 | 0.23 | -47.83 | Pandemic impact, decrease in performance | [Progress on Significant Matters](index=7&type=section&id=3.2%20Analysis%20of%20Progress%2C%20Impact%2C%20and%20Solutions%20for%20Significant%20Matters) During the reporting period, the company continued to manage idle self-owned funds for wealth management and securities investment, and completed the unlocking of the second tranche of restricted shares under the 2017 Restricted Stock Incentive Plan - The company was approved to use up to **RMB 1.5 billion** of idle self-owned funds for cash management, with **RMB 311.8 million** utilized as of March 31, 2020, generating **RMB 3.7906 million** in wealth management income during the reporting period[16](index=16&type=chunk) - The company was approved to use up to **RMB 100 million** of self-owned funds for securities investment, with a securities investment balance of **RMB 0** as of March 31, 2020, and cumulative wealth management income of **RMB 0.9192 million** generated during the reporting period[17](index=17&type=chunk) - The second tranche of restricted shares under the 2017 Restricted Stock Incentive Plan was listed for circulation on March 16, 2020, with **94 incentive recipients** unlocking **646,153 shares**, representing **0.2482%** of the total share capital[18](index=18&type=chunk) [Overdue Unfulfilled Commitments](index=7&type=section&id=3.3%20Overdue%20Unfulfilled%20Commitments%20During%20the%20Reporting%20Period) The company had no overdue unfulfilled commitments during the reporting period - There were no overdue unfulfilled commitments during the reporting period[19](index=19&type=chunk) [Warning on Future Net Profit Forecast](index=8&type=section&id=3.4%20Warning%20and%20Explanation%20Regarding%20Potential%20Loss%20or%20Significant%20Change%20in%20Cumulative%20Net%20Profit%20from%20Year-Beginning%20to%20the%20End%20of%20the%20Next%20Reporting%20Period%20Compared%20to%20the%20Same%20Period%20Last%20Year) The company has not issued a warning regarding a potential loss or significant change in cumulative net profit from the beginning of the year to the end of the next reporting period - The company has not issued a warning regarding potential future cumulative net profit losses or significant changes[20](index=20&type=chunk) [Appendix](index=9&type=section&id=Item%20IV.%20Appendix) This appendix includes the company's financial statements, details on adjustments for new accounting standards, and the audit status of the quarterly report [Financial Statements](index=9&type=section&id=4.1%20Financial%20Statements) This section presents the consolidated and parent company balance sheets, income statements, and cash flow statements for Getein Biotech's first quarter of 2020, illustrating the company's financial position, operating results, and cash flows at the end of the reporting period [Consolidated Balance Sheet](index=9&type=section&id=Consolidated%20Balance%20Sheet) This table provides a summary of the company's consolidated assets, liabilities, and equity as of March 31, 2020 Consolidated Balance Sheet Summary (As of March 31, 2020) | Item | March 31, 2020 (Yuan) | December 31, 2019 (Yuan) | | :--- | :--- | :--- | | Total Current Assets | 1,779,126,867.90 | 1,566,846,024.58 | | Total Non-Current Assets | 454,763,502.90 | 440,793,326.79 | | Total Assets | 2,233,890,370.80 | 2,007,639,351.37 | | Total Current Liabilities | 498,480,248.92 | 316,884,974.30 | | Total Non-Current Liabilities | 8,293,269.85 | 9,099,334.10 | | Total Liabilities | 506,773,518.77 | 325,984,308.40 | | Total Equity Attributable to Parent Company Owners | 1,668,849,332.05 | 1,624,972,044.14 | | Minority Interests | 58,267,519.98 | 56,682,998.83 | | Total Owners' Equity | 1,727,116,852.03 | 1,681,655,042.97 | | Total Liabilities and Owners' Equity | 2,233,890,370.80 | 2,007,639,351.37 | [Parent Company Balance Sheet](index=11&type=section&id=Parent%20Company%20Balance%20Sheet) This table provides a summary of the parent company's assets, liabilities, and equity as of March 31, 2020 Parent Company Balance Sheet Summary (As of March 31, 2020) | Item | March 31, 2020 (Yuan) | December 31, 2019 (Yuan) | | :--- | :--- | :--- | | Total Current Assets | 1,564,640,825.43 | 1,406,258,719.16 | | Total Non-Current Assets | 521,416,352.18 | 495,373,313.16 | | Total Assets | 2,086,057,177.61 | 1,901,632,032.32 | | Total Current Liabilities | 419,667,124.95 | 268,406,511.23 | | Total Non-Current Liabilities | 4,284,958.53 | 5,099,454.19 | | Total Liabilities | 423,952,083.48 | 273,505,965.42 | | Total Owners' Equity | 1,662,105,094.13 | 1,628,126,066.90 | | Total Liabilities and Owners' Equity | 2,086,057,177.61 | 1,901,632,032.32 | [Consolidated Income Statement](index=13&type=section&id=Consolidated%20Income%20Statement) This table presents the consolidated revenues, expenses, and net profit for the first quarter of 2020 compared to the same period in 2019 Consolidated Income Statement Summary (Q1 2020 vs. Q1 2019) | Item | Q1 2020 (Yuan) | Q1 2019 (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 148,162,241.23 | 206,565,571.46 | -28.27 | | Total Operating Costs | 104,560,956.98 | 131,017,726.95 | -20.20 | | Operating Profit | 51,188,726.17 | 98,147,777.16 | -47.90 | | Total Profit | 50,654,611.15 | 98,251,656.86 | -48.44 | | Net Profit | 44,456,989.23 | 86,996,212.83 | -48.89 | | Net Profit Attributable to Parent Company Shareholders | 43,247,242.43 | 84,999,724.84 | -49.12 | | Minority Interest Income | 1,209,746.80 | 1,996,487.99 | -39.32 | | Total Comprehensive Income | 44,463,118.08 | 86,980,342.55 | -48.88 | | Total Comprehensive Income Attributable to Parent Company Owners | 43,253,371.28 | 84,983,854.56 | -49.10 | [Parent Company Income Statement](index=15&type=section&id=Parent%20Company%20Income%20Statement) This table presents the parent company's revenues, expenses, and net profit for the first quarter of 2020 compared to the same period in 2019 Parent Company Income Statement Summary (Q1 2020 vs. Q1 2019) | Item | Q1 2020 (Yuan) | Q1 2019 (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 88,401,626.71 | 158,445,991.38 | -44.21 | | Operating Profit | 37,477,965.83 | 88,574,229.15 | -57.69 | | Total Profit | 36,963,566.67 | 88,774,229.87 | -58.36 | | Net Profit | 33,252,192.55 | 78,202,111.39 | -57.47 | | Total Comprehensive Income | 33,252,192.55 | 78,202,111.39 | -57.47 | [Consolidated Cash Flow Statement](index=17&type=section&id=Consolidated%20Cash%20Flow%20Statement) This table summarizes the consolidated cash flows from operating, investing, and financing activities for the first quarter of 2020 compared to the same period in 2019 Consolidated Cash Flow Statement Summary (Q1 2020 vs. Q1 2019) | Item | Q1 2020 (Yuan) | Q1 2019 (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -46,904,908.02 | -8,390,655.20 | 459.01 | | Net Cash Flow from Investing Activities | 153,921,032.70 | 13,765,986.12 | 1,018.13 | | Net Cash Flow from Financing Activities | 209,096,477.22 | 41,240,666.66 | 407.05 | | Net Increase in Cash and Cash Equivalents | 316,923,994.70 | 46,121,321.72 | 587.15 | | Cash and Cash Equivalents at End of Period | 964,074,390.20 | 189,034,898.17 | 410.01 | [Parent Company Cash Flow Statement](index=18&type=section&id=Parent%20Company%20Cash%20Flow%20Statement) This table summarizes the parent company's cash flows from operating, investing, and financing activities for the first quarter of 2020 compared to the same period in 2019 Parent Company Cash Flow Statement Summary (Q1 2020 vs. Q1 2019) | Item | Q1 2020 (Yuan) | Q1 2019 (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -232,886,301.45 | -77,395,123.77 | 201.04 | | Net Cash Flow from Investing Activities | 138,064,597.24 | 72,616,622.83 | 90.13 | | Net Cash Flow from Financing Activities | 194,175,393.89 | 39,770,666.66 | 388.31 | | Net Increase in Cash and Cash Equivalents | 100,158,964.73 | 34,504,826.75 | 190.28 | | Cash and Cash Equivalents at End of Period | 682,638,131.24 | 152,996,417.04 | 346.24 | [Adjustments for New Revenue Recognition Standards](index=19&type=section&id=4.2%20Adjustments%20to%20Financial%20Statements%20at%20the%20Beginning%20of%20the%20First%20Year%20of%20Adoption%20of%20New%20Revenue%20and%20Lease%20Standards%20Starting%20from%202020) Effective January 1, 2020, the company adopted new revenue recognition standards, primarily reclassifying advance receipts from 'Advance Receipts' to 'Contract Liabilities' in the opening consolidated and parent company balance sheets, without affecting total assets or liabilities [Consolidated Balance Sheet (New Revenue Standard Adjustments)](index=19&type=section&id=Consolidated%20Balance%20Sheet%20(New%20Revenue%20Standard%20Adjustments)) This section details the reclassification of advance receipts to contract liabilities in the consolidated balance sheet due to the adoption of new revenue standards - In accordance with new revenue recognition standards, the company reclassified **RMB 39,686,835.91** from 'Advance Receipts' to 'Contract Liabilities' in the consolidated balance sheet as of December 31, 2019, resulting in 'Advance Receipts' of **RMB 0** and new 'Contract Liabilities' of **RMB 39,686,835.91**[43](index=43&type=chunk)[44](index=44&type=chunk) - This adjustment does not affect the total assets, total liabilities, or total owner's equity in the consolidated balance sheet[44](index=44&type=chunk) [Parent Company Balance Sheet (New Revenue Standard Adjustments)](index=22&type=section&id=Parent%20Company%20Balance%20Sheet%20(New%20Revenue%20Standard%20Adjustments)) This section details the reclassification of advance receipts to contract liabilities in the parent company balance sheet due to the adoption of new revenue standards - In accordance with new revenue recognition standards, the company reclassified **RMB 16,721,850.80** from 'Advance Receipts' to 'Contract Liabilities' in the parent company balance sheet as of December 31, 2019, resulting in 'Advance Receipts' of **RMB 0** and new 'Contract Liabilities' of **RMB 16,721,850.80**[47](index=47&type=chunk)[48](index=48&type=chunk) - This adjustment does not affect the total assets, total liabilities, or total owner's equity in the parent company balance sheet[48](index=48&type=chunk) [Explanation of Retrospective Adjustments for New Standards](index=24&type=section&id=4.3%20Explanation%20of%20Retrospective%20Adjustments%20to%20Prior%20Period%20Comparative%20Data%20for%20First-Time%20Adoption%20of%20New%20Revenue%20and%20Lease%20Standards%20Starting%20from%202020) The company did not retrospectively adjust prior period comparative data for the first-time adoption of new revenue and lease standards starting from 2020 - The company did not retrospectively adjust prior period comparative data to reflect the impact of new revenue and lease standards[49](index=49&type=chunk) [Audit Report](index=24&type=section&id=4.4%20Audit%20Report) This quarterly report is unaudited - This quarterly report is unaudited[6](index=6&type=chunk)

公司代码：603387 公司简称：基蛋生物 基蛋生物科技股份有限公司 2019 年年度报告 二零二零年三月 中国 南京 基蛋生物 2019 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 中天运会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人苏恩本、主管会计工作负责人倪文及会计机构负责人（会计主管人员）倪文声明： 保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司2019年利润分配预案如下：拟以实施权益分派股权登记日登记的总股本为基数（具体日期 将在权益分派实施公告中明确）,向全体股东每10股派发人民币4元（含税），剩余未分配利润结转 以后年度分配，在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总额不变，相 应调整每股分配比例，并将另行公告具体调整情况。以上利润分配预案需提交2019年年度股东大会 通过后实施。 六、 前瞻性陈述的 ...

2019 年第三季度报告 公司代码：603387 公司简称：基蛋生物 基蛋生物科技股份有限公司 2019 年第三季度报告 1 / 27 | 目录 | | --- | 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元币种：人民币 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 8 | | | 本报告期末 | 上年度末 | | 本报告期末比上年 度末增减(%) | | | --- | --- | --- | --- | --- | --- | | 总资产 | 1,723,855,595.83 | 1,570,406,877.59 | | | 9.77 | | 归属于上市公司股东的净 | 1,483,789,396.57 | 1,345,363,852.18 | | | 10.29 | | 资产 | | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | | 比上年同期增减 | | | | （1-9 月） | （1-9 月） | | ...

2019 年半年度报告 公司代码：603387 公司简称：基蛋生物 基蛋生物科技股份有限公司 2019 年半年度报告 二零一九年八月 中国 南京 1 / 137 2019 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人苏恩本、主管会计工作负责人倪文及会计机构负责人（会计主管人员）倪文声明： 保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 公司已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险及应对措施，敬请查 阅第四节"经营情况讨论与分析"之" ...

2019 年第一季度报告 公司代码：603387 公司简称：基蛋生物 基蛋生物科技股份有限公司 2019 年第一季度报告 1 / 24 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 8 | 2019 年第一季度报告 一、 重要提示 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | 单位：元币种：人民币 | | --- | | | 本报告期末 | 上年度末 | 本报告期末比上年度 | | --- | --- | --- | --- | | | | | 末增减(%) | | 总资产 | 1,669,056,010.55 | 1,570,406,877.59 | 6.28 | | 归属于上市公司股东的净 | 1,433,602,004.82 | 1,345,363,852.18 | 6.56 | | 资产 | | | | | | 年初至报告期末 | 上年初至上年报告期 | 比上年同期增减(%) | | | | 末 | | | 经营活动产生的现金流量 | -8,364,415.45 ...

2018 年年度报告 公司代码：603387 公司简称：基蛋生物 基蛋生物科技股份有限公司 2018 年年度报告 二零一九年四月 中国 南京 1 / 163 2018 年年度报告 重要提示 三、 中天运会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人苏恩本、主管会计工作负责人倪文及会计机构负责人（会计主管人员）倪文声明： 保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司 2018 年利润分配预案如下：拟以 2018 年 12 月 31 日公司总股本为基数，向全体股东每 10 股派发人民币 4.1 元（含税），剩余未分配利润结转以后年度分配；以资本公积向全体股东每 10 股转增 4 股，不送红股。以上利润分配预案需提交 2018 年年度股东大会通过后实施。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ ...